Get the Stockscreener App
13.69
0.96%
0.13
CorMedix Inc stock is traded at $13.69, with a volume of 3.46M.
It is up +0.96% in the last 24 hours and up +23.78% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$13.56
Open:
$13.62
24h Volume:
3.46M
Relative Volume:
1.58
Market Cap:
$1.02B
Revenue:
$65,400
Net Income/Loss:
$-46.34M
P/E Ratio:
-14.88
EPS:
-0.92
Net Cash Flow:
$-38.74M
1W Performance:
+5.88%
1M Performance:
+23.78%
6M Performance:
+35.14%
1Y Performance:
+168.43%
1-Day Range:
$13.62
$14.44
1-Week Range:
$12.79
$14.44
52-Week Range:
$5.1001
$17.43
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
13.69 | 977.90M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Leerink Partners | Outperform |
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Aug-26-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
Is Now a Good Time to Reenter CorMedix Inc.July 2025 Sector Moves & Verified Momentum Stock Watchlist - newsyoung.net
NJ Judge Files Corrected Version Of Error-Filled Opinion - Law360
Will CorMedix Inc. Bounce From 52 Week Low2025 Major Catalysts & Trade Opportunity Analysis - mustnews.co.kr
CorMedix (CRMD) Soars 5.1%: Is Further Upside Left in the Stock? - MSN
CorMedix Doubles Down On Infection Prevention With DefenCath Success - Finimize
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 45.63%: Here's is How to Trade - Yahoo Finance
CorMedix’s DEFENCATH® Study: A Potential Game-Changer in Infection Prevention - MSN
Will CorMedix Inc. benefit from AI trendsJuly 2025 Update & Stock Market Timing Techniques - mustnews.co.kr
Why CorMedix Inc. stock attracts strong analyst attentionWeekly Risk Report & Capital Efficiency Focused Ideas - thegnnews.com
Needham Maintains a Buy Rating on CorMedix (CRMD) With a $20 PT - MSN
Cormedix Receives Buy Rating from RBC Capital, Analyst Sees 45% Upside Potential - AInvest
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates - MSN
CorMedix Inc. Advances in Infection Prevention with DEFENCATH® Study - TipRanks
Why CorMedix (CRMD) Might be Well Poised for a Surge - sharewise.com
Cormedix Inc. Advances Pediatric Study on DefenCath® for Infection Prevention - TipRanks
CorMedix's (NASDAQ:CRMD) Earnings Aren't As Good As They Appear - Yahoo Finance
Statutory Earnings May Not Be The Best Way To Understand CorMedix's (NASDAQ:CRMD) True Position - simplywall.st
CorMedix (CRMD.O) Surges 8% — Is It a Technical Trigger or a Broader Sector Play? - AInvest
CorMedix Raises $150M in Convertible Notes Offering - AInvest
Undervalued Healthcare Stocks to Buy: Eli Lilly, CorMedix, and Johnson & Johnson - AInvest
Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks? - ca.finance.yahoo.com
Momentum Screeners Rank CorMedix Inc. in Top 5 TodayAI Screening for Swing Trade Picks Finds Momentum - sundaytimes.kr
CorMedix Inc. Just Beat EPS By 50%: Here's What Analysts Think Will Happen Next - 富途牛牛
CorMedix Completes $150M Convertible Notes Offering - TipRanks
CorMedix completes $150 million convertible notes offering on Nasdaq By Investing.com - Investing.com Nigeria
CorMedix completes $150 million convertible notes offering on Nasdaq - Investing.com
Unpacking CorMedix’s 14.2% Intraday Surge: What’s Driving the Move? - AInvest
CorMedix (CRMD.O) Surges 9.7% Intraday—No Fundamentals, So What's Driving It? - AInvest
CorMedix’s SWOT analysis: acquisition boosts biopharmaceutical stock’s outlook By Investing.com - Investing.com Nigeria
CorMedix’s SWOT analysis: acquisition boosts biopharmaceutical stock’s outlook - Investing.com
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus - Zacks Investment Research
CorMedix Inc. (NASDAQ:CRMD) Q2 2025 Earnings Call Transcript - Insider Monkey
CorMedix Inc. Earnings Call Highlights Strategic Growth - TipRanks
Both Individual Investors Who Control a Good Portion of CorMedix Inc. (NASDAQ:CRMD) Along With Institutions Must Be Dismayed After Last Week's 16% Decrease - 富途牛牛
CorMedix Inc. stock trend outlook and recovery pathShort Squeeze Opportunities with Indicators - Newser
Is CorMedix Inc. part of any ETFShort-Term Gainers List - thegnnews.com
CorMedix Inc. stock trend forecastFree Real-Time Analysis With Entry Targets - Newser
Short Interest Drops in CorMedix Inc. After RallyReal-Time Analysis With Entry Targets In Progress - beatles.ru
Strategic Value and Growth Potential of CorMedix Post-Melinta Acquisition - AInvest
CorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’ - Stocktwits
CorMedix Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
How did CRMD's Q4 earnings surprise impact investor confidence? - AInvest
It's A Story Of Risk Vs Reward With CorMedix Inc. (NASDAQ:CRMD) - simplywall.st
Cormedix Inc Reports Q2 2025 Earnings: $39.7M in Revenue, $0.29 EPS, and Acquisition of Melinta Therapeutics - AInvest
Applying big data sentiment scoring on CorMedix Inc.Free Consistent Income Focused Trade List - Newser
Press Release: Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update - 富途牛牛
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):